Physician profile
Abboud Kawak
NPI 1093789380
$68,285.01
in general payments reported to CMS, 2019-2025
47 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $7,413 · 2021: $7,413 · 2022: $895 · 2023: $1,263 · 2024: $946 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,421 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,420.87 |
| Education | $156.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $49,986.98 | 2019-2025 | Nucala, Trelegy Ellipta |
| Mylan Specialty L.P. | $11,270.75 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $810.93 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $769.24 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Electromed, INC. | $482.81 | 2019-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $459.94 | 2022-2025 | |
| Harmony Biosciences LLC | $332.02 | 2022-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $252.90 | 2019-2025 | Dupixent |
| Genzyme Corporation | $237.98 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $234.98 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Grifols USA, LLC | $217.45 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $215.53 | 2020-2025 | Glassia |
| Merck Sharp & Dohme LLC | $204.58 | 2023-2025 | Zerbaxa, Winrevair, Dificid |
| Genentech USA, INC. | $194.74 | 2019-2023 | Xolair |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abboud Kawak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.